Skip to main content
Clinical Trials/IRCT20200128046294N2
IRCT20200128046294N2
Completed
Phase 3

A prospective randomized controlled trial comparing Sovodak (Sofosbuvir plus Daclatasvir) in participants with moderate to severe Coronavirus disease (COVID-19) compared to standard of care treatment

Digestive Disease Research Institute0 sites70 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Digestive Disease Research Institute
Enrollment
70
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Both genders
  • Age \=18 years at time of signing Informed Consent Form
  • Willing and able to provide written informed consent prior to performing study to any assigned treatment arm
  • Must agree not to enroll in another study of an investigational agent prior to completion of study
  • Will be admitted to Shariati hospital (Tehran), Baharloo (Tehran), Sina (Tehran), Sayyad Shirazi (Gorgan) and not transferred to another hospital
  • Laboratory (RT\-PCR) confirmed infection with 2019\-nCoV
  • Lung involvement confirmed with chest CT scan
  • Hospitalized patients with: Fever (Oral temperature \= 37\.8 ?) and at least one of Respiratory rate \>24/min / O2Sat\<94% or the Pa02/Fi02 ratio \<300mgHg
  • \=8 days since illness onset

Exclusion Criteria

  • Known allergic reaction to Sofosbuvir or Daclatasvir
  • Pregnant or breastfeeding, or positive pregnancy test
  • Receipt of any experimental treatment for COVID\-19 prior to the time of the screening evaluation
  • Heart rate \< 60/min
  • Taking Amiodarone
  • Evidence of multiorgan failure
  • Requiring mechanical ventilation at screening
  • eGFR\< 50 mL/min

Outcomes

Primary Outcomes

Not specified

Similar Trials